Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Kidney Neoplasms: early-phase trial registry
4 of 10 indexed Kidney Neoplasms trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,724 of 28,707 conditions by registered trial count.
10 US clinical trials · 4 currently recruiting · #1,724 of 28,707 conditions by registered trial count
Kidney Neoplasms: 10 US clinical trials tracked, 4 recruiting.
Kidney Neoplasms is the subject of 10 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 3 of these trials.
Enrollment posture brief
Registry condition kidney-neoplasms
OPEN 4 | RECR 40% | LATE 1 | EARLY 6 | RANK #1724 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Acute Myeloid Leukemia (AML) (40% recruiting · 30 trials)
Kidney Neoplasms lists 4 open slots (40% of 10 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Kidney Neoplasms on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Kidney Neoplasms is recruiting below its size-band peers.
4 of 10 indexed trials (40%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Kidney Neoplasms research.
National Cancer Institute (NCI) accounts for 3 of 10 trials (30%). 8 distinct sponsors appear on at least one study for this condition label.
-
Most Kidney Neoplasms trials plan to enrol fewer than 100 people.
Median target enrolment is 69 among the 10 trials that report a genuine target (sentinel values excluded). 7 of those (70%) plan for fewer than 100 participants.
-
Kidney Neoplasms research is mostly interventional.
8 interventional and 2 observational studies make up this index (80% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
10 total, page 1 of 1
Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions
The University of Texas Health Science Center at San Antonio
NCT03160274
Genetic Analysis of Birt Hogg-Dube Syndrome and Characterization of Predisposition to Kidney Cancer
National Cancer Institute (NCI)
NCT00033137
Cryaoablation Assisted Partial Nephrectomy a Non Ischemic Approach
Urological Research Network
NCT05218811
Translation of Acoustic Angiography: Contrast Enhanced Super Resolution (CESR) Imaging
UNC Lineberger Comprehensive Cancer Center
NCT07225114
Savolitinib vs. Sunitinib in MET-driven PRCC.
AstraZeneca
NCT03091192
Study of Safety and Efficacy of Alpelisib With Everolimus or Alpelisib With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors
Novartis Pharmaceuticals
NCT02077933
Cabozantinib for Advanced Urothelial Cancer
National Cancer Institute (NCI)
NCT01688999
Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Renal Cell Carcinoma
Pfizer
NCT00076011
A Phase I Study of Continuous Intravenous Infusion of PSC 833 and Vinblastine in Patients With Metastatic Renal Cancer
National Cancer Institute (NCI)
NCT00001570
Study of Motexafin Gadolinium for the Treatment of Renal Cell (Kidney) Cancer
Pharmacyclics
NCT00134186
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 4 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Kidney Neoplasms records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Kidney Neoplasms trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Kidney Neoplasms page
10 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 4 Kidney Neoplasms trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Kidney Neoplasms trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Kidney Neoplasms condition card totals 10 registered trials; most-linked intervention Vascular Endothelial Growth Factor Receptor [VEGFR] and Platelet-Derived Growth Factor Receptor [PDGFR] inhibitor; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.